I do not expect much revenue in the next 12-24mths.
Looking closer at this, my understanding is
sas is a special access scheme - essentially where ppl get access to drugs not TGA approved. So even if some ppl get access to our drugs wouldn’t expect much revenue as a result of a few ppl. Whoch doctors are gonna give a drug to a patient before rev approvals?
it says this further down..,see pic below
immediate rev from SAS and also future drug sales lost registration.
I really wouldn’t expect much revenue before 2024 l. the big numbers are going to be post ph2 of ahl42 and/or Gad studies at the end of 2023 and any buyouts.
Just probably want to get expectations in check to avoid disappointment - this is biotech.
Nothing for months and months and months and then boom possibility of something huge.
